Vericel Corp

Latest Results (07.10.2025):

Vericel Corp reported strong financial performance for the fourth quarter and full-year 2024, showcasing significant revenue growth, enhanced profitability, and strategic business advancements. The company achieved notable increases in both its MACI and Burn Care segments, while also setting higher mid-term profitability targets.

Revenue Growth

In the full-year 2024, Vericel Corp achieved a total revenue of $237.2 million, marking a 20% increase compared to the previous year. The MACI segment contributed $197.3 million, growing by 20%, while Burn Care revenues rose by 22% to $39.9 million. For the fourth quarter alone, total net revenue reached $75.4 million, a 16% increase year-over-year.

Profitability Enhancements

Vericel reported a full-year adjusted EBITDA growth of 58% to $53.4 million. In the fourth quarter, adjusted EBITDA surged by 34% to $29.9 million, achieving a margin of 40%. The company's gross margin for the full year stood at 73%, increasing by approximately 390 basis points, while the fourth quarter gross margin hit a record 78%.

Net Income Growth

The company’s net income for the full year 2024 was $10.4 million, a significant improvement from a net loss in the previous year. In the fourth quarter, net income rose by 52% to $19.8 million, translating to $0.38 per diluted share.

Mid-Term Profitability Targets

Vericel has increased its mid-term profitability targets, projecting gross margins in the high-70% range and adjusted EBITDA margins in the high-30% range by 2029, reflecting confidence in sustained financial performance.

Business Developments

The fourth quarter saw the highest number of MACI implants and approximately 250 MACI Arthro surgeons trained to date. Additionally, Vericel completed the construction of a new corporate headquarters and manufacturing facility, with commercial manufacturing expected to begin in 2026.

2025 Financial Guidance

Looking ahead, Vericel reaffirmed its 2025 financial guidance, anticipating total revenue growth of 20% to 23%, gross margins between 73% and 74%, and adjusted EBITDA margins of 25% to 26%, underscoring continued growth and profitability.